Department of General Surgery, The First Medical Center of Chinese, PLA General Hospital, Beijing, China.
Department of General Surgery, Chinese PLA Medical School, Beijing, China.
Surg Endosc. 2024 Aug;38(8):4215-4221. doi: 10.1007/s00464-024-10945-1. Epub 2024 Jun 10.
Whether the Western pT1acN0M0 gastric cancer (GC) patients who met the Japanese expanded criteria could be the candidates for endoscopic treatment (ET) remains unclear because of unknown long-term survival outcomes.
A retrospective cohort study using data from the Surveillance, Epidemiology, and End Results (SEER) program was performed. The survival differences between pT1acN0M0 gastric adenocarcinoma patients who received ET or gastrectomy treatment (GT) were evaluated using multivariate survival analysis.
A total of 314 pT1acN0M0 gastric adenocarcinoma patients who met the expanded criteria were included, 46 patients received ET and 268 patients received GT. pT1acN0M0 gastric adenocarcinoma patients met the expanded criteria underwent ET experienced a similar hazard of cancer-specific death compared with those underwent GT both in the multivariate Cox survival analysis (adjusted hazard ratio [HR]; 1.18, 95% confidence interval [CI] 0.40-3.49; P = 0.766) and the multivariate competing risk model (subdistribution HR [SHR], 1.12, 95% CI 0.38-3.29; P = 0.845). The result that pT1acN0M0 gastric adenocarcinoma patients met the expanded criteria underwent ET experienced comparable survival outcomes to those who underwent GT did not change even compared with those who underwent GT with > 15 lymph nodes examined (adjusted HR, 1.55, 95% CI 0.44-5.49; P = 0.499; SHR, 1.47, 95% CI 0.44-4.88; P = 0.532).
The ET can be considered in Western pT1acN0M0 gastric adenocarcinoma patients who met the Japanese expanded criteria. However, a prospective study should be warranted.
符合日本扩大标准的西方 pT1acN0M0 胃癌(GC)患者是否可以成为内镜治疗(ET)的候选者尚不清楚,因为其长期生存结果未知。
使用监测、流行病学和最终结果(SEER)计划的数据进行了回顾性队列研究。使用多变量生存分析评估接受 ET 或胃切除术(GT)治疗的 pT1acN0M0 胃腺癌患者的生存差异。
共纳入 314 例符合扩大标准的 pT1acN0M0 胃腺癌患者,其中 46 例接受 ET,268 例接受 GT。在多变量 Cox 生存分析中,符合扩大标准的 pT1acN0M0 胃腺癌患者接受 ET 的癌症特异性死亡风险与接受 GT 的患者相似(调整后的危险比 [HR];1.18,95%置信区间 [CI] 0.40-3.49;P=0.766)和多变量竞争风险模型(亚分布 HR [SHR],1.12,95%CI 0.38-3.29;P=0.845)。即使与接受 GT 且检查的淋巴结>15 个的患者相比,符合扩大标准的 pT1acN0M0 胃腺癌患者接受 ET 的生存结局与接受 GT 的患者相当的结果也没有改变(调整后的 HR,1.55,95%CI 0.44-5.49;P=0.499;SHR,1.47,95%CI 0.44-4.88;P=0.532)。
对于符合日本扩大标准的西方 pT1acN0M0 胃腺癌患者,可以考虑进行 ET。然而,应该进行前瞻性研究。